Adrenocorticotropin inhibition of mineralocorticoid hormone production.
1. Adrenocorticotropin (ACTH)-induced steroidogenesis, obtained by continuous administration of ACTH for 3 days, produces in man (a) sustained elevations of plasma deoxycorticosterone and cortisol concentrations, (b) transient elevations of plasma aldosterone and 18-hydroxycorticosterone concentrations that return to near-control values, and (c) brisk initial increases in plasma 18-hydroxydeoxycorticosterone and corticosterone concentrations that fall to 20-68% of peak values 30 h thereafter. 2. Dexamethasone (8 mg/day, orally) treatment for 2 days in man permits a greater postural increase in plasma aldosterone and 18-hydroxycortisone concentrations. A dampening effect of ACTH is suggested. 3. An ACTH-initiated inhibition of 11 beta- and 18-hydroxylation is proposed to be operative in regulation of mineralocorticoid hormones.
D015069:18-Hydroxycorticosterone / Q000097:blood; D015070:18-Hydroxydesoxycorticosterone / Q000097:blood; D000307:Adrenal Gland Diseases / Q000503:physiopathology; D000311:Adrenal Glands / Q000502:physiology; D000324:Adrenocorticotropic Hormone; D000328:Adult; D000450:Aldosterone / Q000097:blood; D003345:Corticosterone / Q000097:blood; D003480:Cushing Syndrome / Q000097:blood; D003900:Desoxycorticosterone / Q000097:blood; D003907:Dexamethasone; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007668:Kidney / Q000502:physiology; D008875:Middle Aged; D008901:Mineralocorticoids / Q000097:blood*; D011187:Posture
D015070:18-Hydroxydesoxycorticosterone; D008901:Mineralocorticoids; D003900:Desoxycorticosterone; D000450:Aldosterone; D015069:18-Hydroxycorticosterone; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D003345:Corticosterone; D006854:Hydrocortisone